CAMH to study whether ‘magic mushrooms’ can treat depression without psychedelic effect |

TORONTO – The Centre for Addiction and Mental Health says it has been awarded Canada’s first federal grant to review the consequences of a psychedelic chemical element in “magic mushrooms” on treatment-resistant melancholy.

The psychiatric institute says researchers will discover whether or not experiencing the consequences of psilocybin — present in “magic mushrooms” — is critical for it to have antidepressant results.

The medical trial will recruit 60 adults with treatment-resistant depression over three years and administer a full dose of psilocybin, plus a blocker to stop the psychedelic results, to a random third of individuals.

Learn extra:

First patient in Quebec gets approval from Health Canada for magic mushroom therapy

Dr. Ishrat Husain, head of CAMH’s medical trials unit and principal investigator of the brand new research, says there’s a “rising curiosity and physique of information” on utilizing psychedelic medication for treating psychological sickness and addictions.

Story continues under commercial

He says earlier medical trials involving the chemical element have proven huge and enduring antidepressant results when mixed with intensive psychotherapy.

Husain says if the research exhibits psilocybin can deal with melancholy with out inducing a psychedelic state, it may take away the necessity for psychological help throughout therapy, which is time-intensive and dear.

Click to play video: 'International self-care day: why we need to practice self-care'

Worldwide self-care day: why we have to apply self-care

Worldwide self-care day: why we have to apply self-care

© 2022 The Canadian Press

Leave a Comment